Sichuan Kelun-Biotech Biopharmaceutical Full Year 2024 Earnings: Beats Expectations

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥1.93b (up 26% from FY 2023).
• Net loss: CN¥266.8m (loss narrowed by 49% from FY 2023).
• CN¥1.20 loss per share (improved from CN¥2.84 loss in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sichuan Kelun-Biotech Biopharmaceutical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 8.7%. Earnings per share (EPS) also surpassed analyst estimates by 4.1%.

Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 5.5% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Sichuan Kelun-Biotech Biopharmaceutical's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.